A Phase II Trial of Oxaliplatin, Folinic Acid, and 5-Fluorouracil (FOLFOX4) as First-Line Chemotherapy in Advanced Colorectal Cancer: A China Single-Center Experience

REFERENCES

• Parkin D. M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005; 55(2)74–108
   PubMed Web of Science ®Google Scholar
• Glimelius B., Hoffman K., Graf W., Pahlman L., Sjoden P. O. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Cancer 1994; 73(3)556–562
   Google Scholar
• Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J. Clin. Oncol. 1992; 10(6)896–903
   PubMed Web of Science ®Google Scholar
• Poon M. A., O'Connell M. J., Moertel C. G., Wieand H. S., Cullinan S. A., et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J. Clin. Oncol. 1989; 7(10)n1407–1418
   PubMed Web of Science ®Google Scholar
• De Gramont A., Bosset J. F., Milan C., Rougier P., Bouche O., et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J. Clin. Oncol. 1997; 15(2)808–815
   PubMed Web of Science ®Google Scholar
• Raymond E., Buquet-Fagot C., Djelloul S., Mester J., Cvitkovic E., et al. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 1997; 8(9)876–885
   PubMed Web of Science ®Google Scholar
• De Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 2000; 18(16)2938–2947
   PubMed Web of Science ®Google Scholar
• Giacchetti S., Perpoint B., Zidani R., Le Bail N., Faggiuolo R., et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 2000; 18(1)136–147
   PubMed Web of Science ®Google Scholar
• Goldberg R. M., Sargent D. J., Morton R. F., Fuchs C. S., Ramanathan R. K., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 2004; 22(1)23–30
   PubMed Web of Science ®Google Scholar
• Levi F. A., Zidani R., Vannetzel J. M., Perpoint B., Focan C., et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J. Natl. Cancer Inst. 1994; 86(21)1608–1617
   PubMed Web of Science ®Google Scholar
• De Gramont A., Vignoud J., Tournigand C., Louvet C., Andre T., et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer 1997; 33(2)214–219
   PubMed Web of Science ®Google Scholar
• Andre T., Louvet C., Raymond E., Tournigand C., de Gramont A. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann. Oncol. 1998; 9(11)1251–1253
   PubMed Web of Science ®Google Scholar
• Andre T., Boni C., Mounedji-Boudiaf L., Navarro M., Tabernero J., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 2004; 350(23)2343–2351
   PubMed Web of Science ®Google Scholar
• Tournigand C., Andre T., Achille E., Lledo G., Flesh M., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 2004; 22(2)229–237
   PubMed Web of Science ®Google Scholar
• Maindrault-Goebel F., de Gramont A., Louvet C., Andre T., Carola E., et al. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol. 2000; 11(11)1477–1483
   PubMed Web of Science ®Google Scholar
• Maindrault-Goebel F., Louvet C., Andre T., Carola E., Lotz J. P., et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur. J. Cancer 1999; 35(9)1338–1342
   PubMed Web of Science ®Google Scholar
• Maindrault-Goebel F., de Gramont A., Louvet C., Andre T., Carola E., et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur. J. Cancer 2001; 37(8)1000–1005
   PubMed Web of Science ®Google Scholar
• Cheeseman S. L., Joel S. P., Chester J. D., Wilson G., Dent J. T., Richards F. J., Seymour M. T. A ‘modified de Gramont’ regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br. J. Cancer 2002; 87(4)393–399
   PubMed Web of Science ®Google Scholar
• De Gramont A., Cervantes A., Andre T., Fiiier A., Ledo G. I., et al. OPTIMOX study: FOLFOX 7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer. J. Clin. Oncol. 2004; 22: 3525, (Suppl. 14)
   Google Scholar
• Grothey A., Sargent D., Goldberg R. M., Schmoll H. J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004; 22(7)1209–1214
   PubMed Web of Science ®Google Scholar